Bracco Imaging S.p.A., part of the Bracco Group, is one of the world's leading companies in the diagnostic imaging business. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions that meet medical needs and facilitate clinical solutions.
Bracco Imaging is a subsidiary of Bracco S.p.A, the holding company of the Bracco Group, which also markets Ethical and Over the Counter (OTC) pharmaceutical products in Italy, as well as Advanced Medical Technology systems worldwide. Furthermore, the Bracco Group offers diagnostic services through the Milan-based Centro Diagnostico Italiano (Italian Diagnostic Center).
Bracco Imaging is the only global diagnostic imaging player dedicated to the development of imaging agents and solutions. Imaging agents are pharmaceutical products aimed at supporting diagnosis and monitoring of various pathologies.
Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-Ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS) and Nuclear Medicine through radioactive tracers.
The Company operates in over 90 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. With an ongoing research covering all key modalities, Bracco Imaging has a strong presence in key geographies: North America, through Bracco Diagnostics Inc. headquartered in Princeton, NJ (US), and with an affiliate in Toronto (Canada); Europe, with offices in all major countries; Japan, where it operates through a licensing agreement with Bayer Schering and the Joint Venture Bracco-Eisai Co., Ltd. The Company also operates in Brazil, South Korea, and China through its 70% controlled Joint Venture Bracco Sine Pharmaceutical Corp. Ltd.
Operational investments have been made by Bracco Imaging in order to achieve top quality and compliances with a sustainable ecology friendly production. Manufacturing activities are located in Italy (Ceriano Laghetto, Torviscosa, and Ivrea), Switzerland (Geneva), Japan (Saitama) and China (Shanghai).
The Company is an innovative Research and Development (R&D) player with an efficient process oriented approach and a track record of innovation in the diagnostic imaging industry. R&D activities are managed in the three Research Centers located in Colleretto Giacosa (Italy), Geneva (Switzerland), and Princeton, NJ (US). Each Research Center possesses highly specialized expertise in diverse diagnostic imaging modalities and techniques. Additional development expertise and support functions exist in Milan, Beijing (China), Konstanz (Germany) and Tokyo (Japan). Bracco Imaging also has a number of research collaboration agreements with prestigious University Departments, Hospital-based Research Centers and Biotech Companies in various parts of the world.
September, 15 2016
Bracco Imaging receives approval in Mexico for ultrasound contrast agent
June, 3 2015
Bracco Imaging announces the first echocardiography imaging procedure in US with sulfur hexafluoride lipid-type A microspheres for injectable suspension